Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen.
Braal CL, Hussaarts KGAM, Seuren L, Oomen-de Hoop E, de Bruijn P, Buck SAJ, Bos MEMM, Thijs-Visser MF, Zuetenhorst HJM, Mathijssen-van Stein D, Vastbinder MB, van Leeuwen RWF, van Gelder T, Koolen SLW, Jager A, Mathijssen RHJ. Braal CL, et al. Among authors: buck saj. Breast Cancer Res Treat. 2020 Nov;184(1):107-113. doi: 10.1007/s10549-020-05829-6. Epub 2020 Aug 16. Breast Cancer Res Treat. 2020. PMID: 32803636 Free PMC article. Clinical Trial.
Correction to: Influence of green tea consumption on endoxifen steady-state concentration in breast cancer patients treated with tamoxifen.
Braal CL, Hussaarts KGAM, Seuren L, Oomen-deHoop E, de Bruijn P, Buck SAJ, Bos MEMM, Thijs-Visser MF, Zuetenhorst HJM, Mathijssen-van Stein D, Vastbinder MB, van Leeuwen RWF, van Gelder T, Koolen SLW, Jager A, Mathijssen RHJ. Braal CL, et al. Among authors: buck saj. Breast Cancer Res Treat. 2021 Feb;185(3):889. doi: 10.1007/s10549-020-05979-7. Breast Cancer Res Treat. 2021. PMID: 33226493 Free PMC article. No abstract available.
Cross-resistance and drug sequence in prostate cancer.
Buck SAJ, Koolen SLW, Mathijssen RHJ, de Wit R, van Soest RJ. Buck SAJ, et al. Drug Resist Updat. 2021 May;56:100761. doi: 10.1016/j.drup.2021.100761. Epub 2021 Mar 18. Drug Resist Updat. 2021. PMID: 33799049 Free article. Review.
Continued androgen signalling inhibition improves cabazitaxel efficacy in prostate cancer.
Mout L, van Royen ME, de Ridder C, Stuurman D, van de Geer WS, Marques R, Buck SAJ, French PJ, van de Werken HJG, Mathijssen RHJ, de Wit R, Lolkema MP, van Weerden WM. Mout L, et al. Among authors: buck saj. EBioMedicine. 2021 Nov;73:103681. doi: 10.1016/j.ebiom.2021.103681. Epub 2021 Nov 5. EBioMedicine. 2021. PMID: 34749299 Free PMC article.
Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment.
Buck SAJ, Braal CL, Hofman MM, Oomen-de Hoop E, de Bruijn P, Ghobadi Moghaddam-Helmantel IM, Hussaarts KGAM, Vastbinder MB, van Rossum-Schornagel QC, van Schaik RHN, Jager A, Koolen SLW, Mathijssen RHJ. Buck SAJ, et al. Ther Adv Med Oncol. 2022 Mar 17;14:17588359221081075. doi: 10.1177/17588359221081075. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35321309 Free PMC article.
Influence of Darolutamide on Cabazitaxel Systemic Exposure.
Buck SAJ, Guchelaar NAD, de Bruijn P, Ghobadi Moghaddam-Helmantel IM, Oomen-de Hoop E, Westgeest HM, Hamberg P, Mathijssen-van Stein D, Lolkema MP, Koolen SLW, de Wit R, Mathijssen RHJ. Buck SAJ, et al. Clin Pharmacokinet. 2022 Oct;61(10):1471-1473. doi: 10.1007/s40262-022-01159-6. Epub 2022 Jul 27. Clin Pharmacokinet. 2022. PMID: 35895277 No abstract available.
CABA-V7: a prospective biomarker selected trial of cabazitaxel treatment in AR-V7 positive prostate cancer patients.
Isebia KT, Mostert B, Belderbos BPS, Buck SAJ, Helmijr JCA, Kraan J, Beaufort CM, Van MN, Oomen-de Hoop E, Sieuwerts AM, van IJcken WFJ, van den Hout-van Vroonhoven MCGN, Brouwer RWW, Oole E, Hamberg P, Haberkorn BCM, Helgason HH, de Wit R, Sleijfer S, Mathijssen RHJ, Martens JWM, Jansen MPHM, van Riet J, Lolkema MP. Isebia KT, et al. Among authors: buck saj. Eur J Cancer. 2022 Dec;177:33-44. doi: 10.1016/j.ejca.2022.09.032. Epub 2022 Oct 6. Eur J Cancer. 2022. PMID: 36323051 Free article.
Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant Prostate Cancer.
Omlin A, Cathomas R, von Amsberg G, Reuter C, Feyerabend S, Loidl W, Boegemann M, Lorch A, Heidenreich A, Tsaur I, Larcher-Senn J, Buck SAJ, Mathijssen RHJ, Jaehde U, Gillessen S, Joerger M. Omlin A, et al. Among authors: buck saj. Clin Cancer Res. 2023 May 15;29(10):1887-1893. doi: 10.1158/1078-0432.CCR-22-3360. Clin Cancer Res. 2023. PMID: 36917691 Clinical Trial.
17 results